447,237 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Millennium Management LLC

Millennium Management LLC acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 447,237 shares of the biopharmaceutical company's stock, valued at approximately $3,819,000. Millennium Management LLC owned approximately 0.28% of Ocular Therapeutix as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Deep Track Capital LP raised its stake in Ocular Therapeutix by 0.9% in the fourth quarter. Deep Track Capital LP now owns 12,836,282 shares of the biopharmaceutical company's stock worth $109,622,000 after buying an additional 114,822 shares in the last quarter. Vanguard Group Inc. raised its stake in Ocular Therapeutix by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after buying an additional 99,730 shares in the last quarter. Deltec Asset Management LLC raised its stake in Ocular Therapeutix by 0.6% in the fourth quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after buying an additional 16,300 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in Ocular Therapeutix by 26.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock worth $11,398,000 after buying an additional 278,610 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Ocular Therapeutix by 5.5% in the fourth quarter. Northern Trust Corp now owns 1,314,871 shares of the biopharmaceutical company's stock worth $11,229,000 after buying an additional 68,174 shares in the last quarter. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL traded down $0.13 during mid-day trading on Friday, hitting $8.01. The stock had a trading volume of 2,177,691 shares, compared to its average volume of 1,399,863. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a 50 day moving average of $7.37 and a two-hundred day moving average of $7.91. Ocular Therapeutix, Inc. has a twelve month low of $4.79 and a twelve month high of $11.78. The firm has a market cap of $1.28 billion, a PE ratio of -6.07 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Insider Activity at Ocular Therapeutix

In other news, Director Richard L. Md Lindstrom bought 10,000 shares of the stock in a transaction dated Thursday, May 8th. The shares were acquired at an average cost of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Pravin Dugel sold 21,219 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider now directly owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,079 shares of company stock valued at $208,739 in the last ninety days. Company insiders own 2.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on OCUL. William Blair began coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. Needham & Company LLC reduced their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. JMP Securities set a $19.00 price target on Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.